Natasha B. Leighl
Princess Margaret Cancer Centre(CA)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer(2015)6,155 cited
- → Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline(2018)3,616 cited
- → Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial(2014)1,763 cited
- → Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL(2009)1,507 cited
- → Sensitive tumour detection and classification using plasma cell-free DNA methylomes(2018)987 cited
- → Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update(2015)891 cited
- → Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes(2017)774 cited
- → CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer(2018)773 cited
- → Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update(2017)646 cited
- → Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer(2021)607 cited